© 2022 MJH Life Sciences and AJMC - Managed Care News, Research, and Expert Insights. All rights reserved.
© 2022 MJH Life Sciences™ and Clinical Care Targeted Communications, LLC. All rights reserved.
March 07, 2022
This article presents an evaluation of testosterone marketing practices around the period of the testosterone label warning by physician specialty and rural vs urban primary care service area.
August 23, 2021
Although previous work has found lower costs for biosimilar filgrastim compared with reference filgrastim, this study found that site of care can change this calculus, reducing savings.
August 13, 2019
Treatment delays limit the social value generated by chimeric antigen receptor (CAR) T-cell therapy for the treatment of pediatric acute lymphoblastic leukemia and diffuse large B-cell lymphoma.
September 29, 2017
Medicare formularies were inconsistent in increasing restrictiveness to drugs that received FDA black box warnings for death and/or cardiovascular risk with safer available drug alternatives.
May 17, 2011
We measured the financial consequences of new CRC treatment regimens. New regimens have increased cost directly through price and indirectly through nonstandard and second-line regimen use.
March 22, 2011
This study investigates the potential impact of new medical loss ratio regulation on the individual market for health insurance in the United States.
December 01, 2008
Biologic therapy for rheumatoid arthritis or multiple sclerosis was associated with lower use of some types of medical services within 2 to 3 years of initiation.
January 01, 2006